生物技术领域的授权协议（2020-2026）

本报告对全球生物技术领域的授权协议进行研究和分析，深入探讨了企业如何建立授权合作关係、协商财务条款以及分配开发和商业化权利。

目录

摘要整理

第一章：引言

第二章：许可协议趋势

• 引言
• 许可协议的定义
• 授权协议趋势（2020年至今）
  • 许可协议：依年份
  • 许可协议：依研发阶段
  • 授权协议：依行业
  • 许可协议：依治疗领域
  • 授权协议：依技术类型
  • 最活跃公司的授权协议
• 签订许可合作协议的原因
• 许可的未来协议

第三章 许可合约架构概论

• 引言
• 许可合约结构

第四章：主要许可合约

• 引言
• 依价值排名的顶级许可合约

第五章：最活跃的25家授权公司

• 引言
• 最活跃的25家授权公司

第六章：许可合约（含合约目录）

• 引言
• 许可合约及合约文件
• 合约目录
• 合约目录 - 许可合约：依公司分类 （A-Z）
• 合约目录 - 许可合约：依治疗领域分类
• 合约目录 - 授权协议：依技术类型分类
• 关于 Biopharma Research Ltd
• 当前合作伙伴
• 当前协议
• 现任合作伙伴近期报告标题

Benchmark Licensing Partnerships Across the Global Biotechnology Industry

Free report sample

The Licensing Deals in Biotechnology 2020-2026 report provides a comprehensive analysis of licensing agreements across the global biotechnology sector. Designed for business development, licensing, legal, and strategy professionals, the report delivers detailed insight into how companies structure licensing partnerships, negotiate financial terms, and allocate development and commercialization rights.

Fully revised and updated, the report provides detailed information on 2,500+ biotechnology licensing deals announced between 2020 and 2026, offering a broad view of licensing activity across emerging technologies and therapeutic areas. Each transaction includes financial information where available and links to online deal records and contract documents filed with regulators when publicly disclosed.

By combining detailed deal data, financial benchmarking, and access to real contract agreements, the report provides valuable intelligence for evaluating partners, structuring licensing agreements, and negotiating stronger deal terms.

Key Benefits

• Save Significant Research Time

Access a comprehensive database of biotechnology licensing deals instead of searching multiple databases, press releases, and regulatory filings.

• Benchmark Licensing Deal Structures

Understand how biotechnology companies structure licensing partnerships, including development responsibilities, territorial rights, and commercialization arrangements.

• Analyze Financial Terms with Confidence

Review disclosed financial terms including upfront payments, milestone payments, and royalty structures, enabling accurate benchmarking of licensing deal value.

• Access Real Contract Documents

Where available, review actual licensing agreements filed with the SEC, providing deeper insight into the contractual provisions behind real-world deals.

• Identify Active Licensing Dealmakers

Discover which biotechnology companies are most active in licensing partnerships and analyze their dealmaking strategies.

• Track Industry Trends

Analyze licensing activity since 2020 across companies, therapeutic areas, and technologies to understand how partnering strategies are evolving in the biotech sector.

What's Included in the Report

Analysis of biotechnology licensing dealmaking trends since 2020

Overview of licensing deal structures and financial models

Review of leading licensing deals by disclosed value

Profiles of the top 25 most active licensing dealmakers

Detailed analysis of deals organized by company, therapeutic area, technology type, and industry segment

A comprehensive deal directory covering licensing deals announced since 2020

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual licensing contracts, the report enables users to evaluate key partnership provisions such as:

• Rights granted or optioned under the license
• Upfront payments, milestones, and royalty structures
• Intellectual property ownership and licensing scope
• Development, manufacturing, and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration and termination clauses
• Analyzing these agreements provides valuable insight into how licensing partnerships are negotiated and structured across the biotechnology industry.
• Why This Report Matters
• Licensing partnerships are central to innovation in biotechnology, allowing companies to access new technologies, share development risk, and accelerate product development.
• By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to structure stronger licensing partnerships and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing dealmaking

• 2.1. Introduction
• 2.2. Definition of licensing deal
• 2.3. Trends in licensing deals since 2020
  • 2.3.1. Licensing dealmaking by year
  • 2.3.2. Licensing dealmaking by phase of development
  • 2.3.3. Licensing dealmaking by industry sector
  • 2.3.4. Licensing dealmaking by therapy area
  • 2.3.5. Licensing dealmaking by technology type
  • 2.3.6. Licensing dealmaking by most active company
• 2.4. Reasons for entering into licensing partnering deals
• 2.5. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

• 3.1. Introduction
• 3.2. Licensing agreement structure

Chapter 4 - Leading licensing deals

• 4.1. Introduction
• 4.2. Top licensing deals by value

Chapter 5 - Top 25 most active licensing dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active licensing dealmakers

Chapter 6 - Licensing deals including contracts directory

• 6.1. Introduction
• 6.2. Licensing deals with contracts
• Deal directory
• Deal directory - licensing dealmaking by companies A-Z
• Deal directory - licensing dealmaking by therapy area
• Deal directory - licensing dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of licensing
• Figure 2: Trends in licensing deal announcements
• Figure 3: Licensing deals signed at each phase of development
• Figure 4: Licensing deals by industry sector
• Figure 5: Licensing deals by therapy area
• Figure 6: Licensing deals by technology type
• Figure 7: Top 25 most active licensing dealmakers
• Figure 8: Top licensing deals by value
• Figure 9: Most active licensing dealmakers